Moscow, June 10, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) announces the data of the Ministry of Health of the Kingdom of Bahrain on the Russian Sputnik V coronavirus vaccine confirming its safety and high efficacy during the vaccination campaign in the country.
An efficacy study was conducted in Bahrain in accordance with WHO guidelines involving more than 5,000 subjects. Overall efficacy beyond 14 days after administering the second dose was estimated at 94.3%. Analysis is based on the data collected between February and early May 2021.
The data of the Ministry of Health also demonstrates that 98.6% of all COVID-19 cases 14 days after receiving the second dose were mild among those vaccinated with Sputnik V.
Vaccination data indicates high safety of Sputnik V:
· No serious adverse events associated with vaccination;
· No deaths related to the vaccination;
· No cerebral vein thrombosis (CVT) cases after vaccination.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund (RDIF), said:
“Sputnik V has demonstrated efficacy of 94.3% and high safety confirming the data collected in a number of other countries where it is used to protect the population against coronavirus. The Russian vaccine is an important part of Bahrain’s diversified national portfolio. Use of Sputnik V is making a significant contribution in mitigating the spread of coronavirus, resuming normal life and economic activity.”
HE Faeqa Saeed Al-Saleh, Bahrain’s Minister of Health, said:
“Our data has confirmed the high efficacy and safety of Sputnik V during its use in Bahrain. This vaccine is one of a number of approved vaccines made available free of charge to citizens and residents in the Kingdom. Sputnik V continues to play an important role in the Kingdom’s ongoing and successful vaccination campaign, with 81% of the eligible population vaccinated so far.”
Sputnik V has a number of key advantages:
· Efficacy of Sputnik V is 97.6% based on the analysis of data on the coronavirus infection rate among those in Russia vaccinated with both components of Sputnik V from December 5, 2020 to March 31, 2021;
· The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors, which cause the common cold and have been around for thousands of years.
· Sputnik V vector vaccine coronavirus Gamaleya Center uses two different vectors for the two shots in a course of vaccination, providing immunity with a longer duration than vaccines using the same delivery mechanism for both shots.
· The safety, efficacy and lack of negative long-term effects of adenoviral vaccines have been proven by more than 250 clinical studies over two decades.
· There are no strong allergies caused by Sputnik V registered vaccine against COVID 19 Russian Direct Investment Fund.
· The storage temperature of Sputnik V at +2+8 C means it can be stored in a conventional refrigerator without any need to invest in additional cold-chain infrastructure.
· The price of Sputnik V is less than $10 per shot, making it affordable around the world.
***
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling RUB 2.1 tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at www.rdif.ru
For additional information contact:
Alexey Urazov Andrew Leach / Maria Shiryaevskaya
Russian Direct Investment Fund Hudson Sandler
Director for External Communications
Mobile: +7 915 312 76 65 Tel: +44 (0) 20 7796 4133
E-mail: [email protected]
Message has been successfully sent!
